PDF herunterladen
Thromb Haemost 1990; 64(01): 138-144
DOI: 10.1055/s-0038-1647270
Original Article
Schattauer GmbH Stuttgart

The Role of Factor VII in Haemostasis: Infusion Studies of Factor VIIa in a Canine Model of Factor VIII Deficiency

Koen Mertens
1   The Department of Blood Coagulation, Central Laboratory of the Netherlands Red Cross Blood Transfusion Service, Amsterdam, The Netherlands
,
Ernest Briët
2   Haemostasis and Thrombosis Research Unit, Leiden University Hospital, Leiden, The Netherlands
,
Alan R Giles
3   Departments of Pathology and Medicine, Queen’s University, Kingston, Ontario, Canada
› Institutsangaben
Weitere Informationen

Publikationsverlauf

Received 31. Juli 1989

Accepted after revision 19. April 1990

Publikationsdatum:
04. September 2018 (online)

Auch verfügbar auf
  als PDF herunterladen  Lizenzen und Reprints

Summary

The role of factor VIIa in haemostasis has been studied using a canine model of factor VIII deficiency. Highly purified human factor VIIa was administered to dogs at a dosage of 0.5 μg/kg. At selected times pre- and post-infusion, haemostasis was evaluated by the cuticle bleeding time. Plasma was collected for the assay of various parameters, including fibrinopeptide A (FPA) as a marker for thrombin generation in vivo. Factor VIIa infusion resulted in a 6-fold increase of factor VII clotting activity with z t1/2 of 2 h. FPA levels which were 1.4 ng/ml before infusion, did not increase significantly in haemophilic dogs. In normal dogs, however, FPA levels rose to a mean value of 190 ng/ml 30 min post-infusion. It appeared that thrombin generation by factor VIIa infusion had occurred mainly via the intrinsic, factor VIIIdependent pathway. In factor VIII-deficient dogs, factor VIIa infusion did not correct cuticle bleeding, but an inconsistent haemostatic effect was observed 15–30 min post-infusion. Similar results were obtained in haemophilic dogs with circulating antibodies against factor VIII. The haemostatic effectivity could not be improved by increasing the factor VIIa dosage up to 40-fold. Although these data suggest that the extrinsic, factor VIIdependent factor X activation provides only a minor pathway of thrombin generation in vivo, it is possible that the suboptimal haemostatic effect noted may be promoted in bleeding situations where tissue factor availability is less limited. As such, factor VIIa may prove useful in the treatment of haemophilia A patients with acquired inhibitors to factor VIII.

 

  • References

  • 1 Nemerson Y. Tissue factor and hemostasis. Blood 1988; 71: 1-8
    PubMedGoogle Scholar
  • 2 Nemerson Y. The reaction between bovine brain tissue factor and factors VII and X. Biochemistry 1966; 5: 601-608
    CrossrefPubMedGoogle Scholar
  • 3 Macfarlane RG. An enzyme cascade in the blood clotting mechanism and its function as a biological amplifier. Nature 1964; 202: 498-499
    CrossrefPubMedGoogle Scholar
  • 4 Davie EW, Ratnoff OD. Waterfall sequence for intrinsic blood clotting. Science 1964; 145: 1310-1312
    CrossrefPubMedGoogle Scholar
  • 5 Biggs R, Nossel HL. Tissue extract and the contact reaction in blood coagulation. Thromb Diath Haemorrh 1961; 6: 1-14
    PubMedGoogle Scholar
  • 6 Josso F, Prou-Wartelle O. Interaction of tissue factor and factor VII at the earliest phase of coagulation. Thromb Diath Haemorrh 1965; (Suppl. 17) (Suppl.) 35-44
    PubMedGoogle Scholar
  • 7 Østerud B, Rapaport SI. Activation of factor IX by the reaction product of tissue factor and factor VII: Additional pathway for initiating blood coagulation. Proc Natl Acad Sci USA 1977; 74: 5260-5264
    CrossrefPubMedGoogle Scholar
  • 8 Nemerson Y, Zur M. Is hemophilia a disease of the tissue factor pathway of coagulation?. In: Progress in Clinical and Biological Research Vol 72 – Hemophilia and Hemostasis Mènachè D, Surgenor DM, Anderson H. (eds) Alan R Liss Inc; New York: 1981. pp 77-83
  • 9 Østerud B, Rapaport SI. Activation of 125I-factor IX and 125I-factor X: Effect of tissue factor and factor VII, factor Xa and thrombin. Scand J Haematol 1980; 24: 213-226
    PubMedGoogle Scholar
  • 10 Morrison S, Jesty J. Tissue factor-dependent activation of tritium-labeled factor IX and factor X in human plasma. Blood 1984; 63: 1338-1347
    PubMedGoogle Scholar
  • 11 Wam-Cramer BJ, Bajaj SP. Intrinsic versus extrinsic coagulation: kinetic considerations. Biochem J 1986; 239: 757-762
    CrossrefPubMedGoogle Scholar
  • 12 Bom VJ J, van Hinsbergh VW M, Reinalda-Poot JH, Mohanlal RW, Bertina RM. Extrinsic activation of human coagulation factors IX and X on the endothelial surface. Thromb Haemostas 1987; 58: 522 (Abstr 1931)
    PubMedGoogle Scholar
  • 13 Marlar RA, Kleiss AJ, Griffin JH. An alternative extrinsic pathway of human blood coagulation. Blood 1982; 60: 1353-1358
    PubMedGoogle Scholar
  • 14 Stem DM, Nawroth P, Handley D, Kisiel W. An endothelial cell-dependent pathway of coagulation. Proc Natl Acad Sci USA 1985; 82: 2523-2527
    CrossrefPubMedGoogle Scholar
  • 15 Hedner U, Kisiel W. Use of human factor Vila in the treatment of two hemophilia A patients with high-titer inhibitors. J Clin Invest 1983; 71: 1836-1841
    CrossrefPubMedGoogle Scholar
  • 16 Giles AR, Tinlin S, Greenwood R. A canine model of hemophilic (factor VIII:C deficiency) bleeding. Blood 1982; 60: 727-730
    PubMedGoogle Scholar
  • 17 Pijnappels MI M, Briët E, van der Zwet GTh, Huisden R, van Tilburg NH, Eulderink F. Evaluation of the cuticle bleeding time in canine haemophilia A. Thromb Haemostas 1986; 55: 70-73
    PubMedGoogle Scholar
  • 18 Denson KW E, Biggs R. Laboratory diagnosis, tests of clotting function and their standardization. In: Human Blood Coagulation, Haemostasis and Thrombosis Biggs R. (ed) Blackwell Scientific Publications; Oxford: 1976. pp 310-364
  • 19 Thomson JM. Laboratory control of anticoagulant therapy. In: Blood Coagulation and Hemostasis Thomson JM. (ed) Churchill Livingstone; New York: 1980. pp 316-325
  • 20 Leeksma OC, Meijer-Huizinga F, Stoepman-van Dalen EA, van Aken WG, van Mourik JA. Fibrinopeptide A in urine from patients with venous thromboembolism, disseminated intravascular coagulation and rheumatoid arthritis. Evidence for dephosphorylation and carboxyterminal degradation of the peptide by the kidney. Thromb Haemostas 1985; 54: 792-798
    PubMedGoogle Scholar
  • 21 Seligsohn U, Østerud B, Rapaport SI. A coupled amidolytic assay for factor VTI: its use with a clotting assay to determine the activity state of factor VII. Blood 1978; 52: 978-988
    PubMedGoogle Scholar
  • 22 Mertens K, Cupers R, van Wijngaarden A, Bertina RM. Binding of human blood-coagulation factors IXa and X to phospholipid membranes. Biochem J 1984; 223: 588-605
    PubMedGoogle Scholar
  • 23 Mertens K, Bertina RM. The contribution of Ca2+ and phospholipids to the activation of human blood-coagulation factor X by activated factor IX. Biochem J 1984; 223: 607-615
    CrossrefPubMedGoogle Scholar
  • 24 Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976; 72: 248-254
    CrossrefPubMedGoogle Scholar
  • 25 Mertens K, Bertina RM. Pathways in the activation of human coagulation factor X. Biochem J 1980; 185: 647-658
    CrossrefPubMedGoogle Scholar
  • 26 Heystek J, Brummelhuis HG J, Krijnen HW. Contributions to the optimal use of human blood. II. The large-scale preparation of prothrombin complex. Vox Sang 1973; 25: 113-123
    CrossrefPubMedGoogle Scholar
  • 27 Tankersley DL, Alving BM, Finlayson JS. Preparation of β-XIIa (Hageman factor fragment) from human plasma. Thromb Res 1982; 25: 307-317
    CrossrefPubMedGoogle Scholar
  • 28 Mertens K, Giles AR, Brietz E. Assessment of factor VUI-bypassing activity of factor Vila in a canine model of hemophilia. Thromb Haemostas 1985; 54: 258 (Abstr 1529)
    PubMedGoogle Scholar
  • 29 Giles AR, Tinlin S, Hoogendoom H, Fournel MA, Ng P, Pancham N. In vivo characterization of recombinant factor VIII in a canine model of hemophilia (factor VIII deficiency). Blood 1988; 72: 335-339
    PubMedGoogle Scholar
  • 30 Giles AR, Mann KG, Nesheim ME. A combination of factor Xa and phosphatidylcholine-phosphatidylserine vesicles bypasses factor VIII in vivo. Br J Haematol 1988; 69: 491-497
    CrossrefPubMedGoogle Scholar
  • 31 O,Brien DP, Giles AR, Tate KM, Vehar GA. Factor VIII-bypassing activity of bovine tissue factor using the canine hemophilic model. J Clin Invest 1988; 82: 206-11
    CrossrefPubMedGoogle Scholar
  • 32 Seligsohn U, Kasper CK, østerud B, Rapaport SI. Activated factor VII: Presence in factor IX concentrates and persistence in the circulation after infusion. Blood 1979; 53: 828-37
    PubMedGoogle Scholar
  • 33 Broze GJ, Warren LA, Novotny WF, Higuchi DA, Girard JJ, Miletich JP. The lipoprotein-associated coagulation inhibitor that inhibits the factor Vlla-tissue factor complex also inhibits factor Xa: insight into its possible mechanism of action. Blood 1988; 71: 335-343
    PubMedGoogle Scholar
  • 34 Kondo K, Kisiel W. Evidence that plasma lipoproteins inhibit the factor VII a-tissue factor complex by a different mechanism than extrinsic pathway inhibitor. Blood 1987; 70: 1947-1954
    PubMedGoogle Scholar
  • 35 Mertens K, Bertina RM. Activation of human coagulation factor VIII by activated factor X, the common product of the intrinsic and extrinsic pathway of blood coagulation. Thromb Haemostas 1982; 47: 96-100
    PubMedGoogle Scholar
  • 36 Brinkhous KM, Hedner U, Garris JB, Diness V, Read MS. Effect of recombinant factor Vila on the hemostatic defect in dogs with hemophilia A, hemophilia B and von Willebrand disease. Proc Natl Acad Sci USA 1988; 86: 1382-1386
    PubMedGoogle Scholar
  • 37 Brinkhous KM, Sandberg H, Garris JB, Mattsson C, Palm M, Griggs T, Read MS. Purified human factor VIII procoagulant protein: Comparative hemostatic response after infusions into hemophilic and von Willebrand disease dogs. Proc Natl Acad Sci USA 1985; 82: 8752-8756
    CrossrefPubMedGoogle Scholar
  • 38 Silverberg SA, Nemerson Y, Zur M. Kinetics of the activation of bovine coagulation factor X by components of the extrinsic pathway. J Biol Chem 1977; 252: 8481-8488
    PubMedGoogle Scholar
  • 39 Bom VJ J, Bertina RM. The contributions of Ca2+, phospholipids and tissue-factor apoprotein to the activation of human blood-coagulation factor X by activated factor VII. Biochem J 1990; 265: 327-336
    CrossrefPubMedGoogle Scholar
  • 40 Rapaport SI. Inhibition of factor VIIa/tissue factor-induced blood coagulation: with particular emphasis upon a factor Xa-dependent inhibitory mechanism. Blood 1989; 73: 359-365
    PubMedGoogle Scholar
  • 41 Hedner U, Glazer S, Pingel K, Alberts KA, Blombäck M, Schulman S, Johnsson H. Successful use of recombinant factor Vila in patient with severe haemophilia A during synovectomy. Lancet 1988; 2: 1193
    PubMedGoogle Scholar
  • 42 Macik BG, Hohneker J, Roberts HR, Griffin AM. Use of recombinant activated factor VII for treatment of a retropharyngeal hemorrhage in a hemophilic patient with high titer inhibitor. Am J Hematol 1989; 32: 232-234
    CrossrefPubMedGoogle Scholar